Carbenoxolone disodium
Based on 10 publication(s) in Google Scholar
Carbenoxolone disodium is the active metabolite of Glycyrrhizic acid (HY-N0184) and the inhibitor of human 11β-HSD and bacterial 3α, 20β-HSD. Carbenoxolone disodium is an uncoupling agent for gap junctions and a potent inhibitor of Vaccinia virus replication. Carbenoxolone disodium is used for the study of peptic, esophageal and oral ulceration and inflammation. Carbenoxolone disodium inhibits Vaccinia virus replication.
For research use only. We do not sell to patients.
- Purity: 99.94%
- CAS No.: 7421-40-1
- Formula: C34H48Na2O7
- Molecular Weight:614.72
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Antibacterial Compound Library
HY-L049
-
NMPA-Approved Drug Library
HY-L053
-
Cytoskeleton Compound Library
HY-L060
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Rare Diseases Drug Library
HY-L102
-
Anti-Orthopoxvirus Compound Library
HY-L127
-
Off-patent Drug Library
HY-L141
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
FDA-Approved Drug Library
HY-L022
-
Antiviral Compound Library
HY-L027
-
Drug Repurposing Compound Library
HY-L035
Publications Citing Use of MedChemExpress (MCE) Carbenoxolone disodium
More- Nat Neurosci. 2024 Aug;27(8):1522-1533. [Abstract]
- Cell Chem Biol. 2025 Jun 19;32(6):885-898.e11. [Abstract]
- Free Radic Biol Med. 2025 Feb 1:227:64-79. [Abstract]
- Free Radic Biol Med. 2024 Nov 20:225:641-653. [Abstract]
- Transl Res. 2024 May 9:271:26-39. [Abstract]
- Glia. 2025 Apr 4. [Abstract]
- PLoS Pathog. 2026 Jan 26;22(1):e1013903. [Abstract]
- Biol Reprod. 2025 May 13;112(5):942-954. [Abstract]
- Food Chem Toxicol. 2024 May:187:114594. [Abstract]
- Res Sq. 2025 Sep 11.
Customer Validation & Images
-
WB
-
Cell Imaging/Staining
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
-
WB
Biological Activity
IC50: human 11β-HSD; bacterial 3α, 20β-HSD[1]; gap junction; Vaccinia virus[2]
Carbenoxolone disodium (6-150 μM; pre-treatment 1 hour) inhibits Vaccinia virus (VACV) replication in a gap junction-independent in HaCaT cells, and it has toxicity effects on VACV-A5L-EGFP infected cells at 48 h[2].Carbenoxolone (30 μM; pre-treatment 1 hour) does not upregulate PP2A expression, but induces the late protein A27 expression in hacat cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HaCaT cells
-
Concentration:6 μM, 12 μM, 30 μM, 60 μM, 150 μM
-
Incubation Time:Pre-treatment 1 hour
-
Result:Had no toxicity until 48 hours at high dose in virus-infected cells.
-
Cell Line:HaCaT cells
-
Concentration:30 μM
-
Incubation Time:Pre-treatment 1 hour
-
Result:Presented an obvious upregulation of A27.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BALB/c mice[3]
-
Dosage:100, 200 and 300 mg/kg
-
Administration:Intraperitoneal injection; 30, 60 and 60 min before Pentylenetetrazole
-
Result:Significantly increased the sleeping time in mice.
Chemical Information
-
CAS No. 7421-40-1
-
Appearance Solid
-
Molecular Weight 614.72
-
Formula C34H48Na2O7
-
Color White to off-white
-
SMILES
CC(C)([C@]1([H])CC[C@@]([C@@]2(CC[C@]3(CC[C@](C[C@@]3([H])C2=C4)(C)C(O[Na])=O)C)C)5C)[C@@H](OC(CCC(O[Na])=O)=O)CC[C@]1(C)[C@@]5([H])C4=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Nat Neurosci
Spatiotemporally selective astrocytic ATP dynamics encode injury information sensed by microglia following brain injury in mice. [Abstract]2024 Aug;27(8):1522-1533. PMID: 38862791
Carbenoxolone disodium purchased from MedChemExpress. Usage Cited in: Nat Neurosci. 2024 Aug;27(8):1522-1533. [Abstract]
The gap-junction dependency of FLA-evoked astrocytic Ca2+ wave and ATP bursts (n = 10/9/7 slices from 4/4/3 mice for ACSF, 1-Octanol and Carbenoxolone disodium; CBX; 100 µM; 5 min).
-
Cell Chem Biol
Electrochemical sensor toolkit for simultaneous glutamate detection at edge of cleft and peri-soma. [Abstract]2025 Jun 19;32(6):885-898.e11. PMID: 40466640 -
Free Radic Biol Med
Zinc ions facilitate metabolic bioenergetic recovery post spinal cord injury by activating microglial mitophagy through the STAT3-FOXO3a-SOD2 pathway. [Abstract]2025 Feb 1:227:64-79. PMID: 39613048
Carbenoxolone disodium purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Feb 1:227:64-79. [Abstract]
Western blot analysis of p-FOXO3a (S253) and FOXO3a protein in BV2 cells post-Carbenoxolone disodium (CBX; 100 μM) and H₂O₂/zinc treatment.
-
Free Radic Biol Med
Connexin30-deficient mice increase susceptibility to noise via redox and lactate imbalances. [Abstract]2024 Nov 20:225:641-653. PMID: 39396580 -
Transl Res
Counteracting TGM2 by a Fibroin peptide ameliorated Adriamycin-induced nephropathy via regulation of lipid metabolism through PANX1-PPAR α/PANK1 pathway. [Abstract]2024 May 9:271:26-39. PMID: 38734063
Carbenoxolone disodium purchased from MedChemExpress. Usage Cited in: Transl Res. 2024 May 9:271:26-39. [Abstract]
HK-2 cells were treated with PANX1 inhibitor PBN (1 mM),and Carbenoxolone disodium (CBX; 100 μM) with or without ADR. Intracellular lipid content was detected by oil red O staining.
Carbenoxolone disodium purchased from MedChemExpress. Usage Cited in: Transl Res. 2024 May 9:271:26-39. [Abstract]
HK-2 cells were treated with PANX1 inhibitor PBN (1 mM), and Carbenoxolone disodium (CBX; 100 μM) with or without ADR. The protein expressions of Fibronectin, PANX1, PPAR α, and PANK1 were analyzed by western blotting.
-
Glia
Role of Cx43 and ACKR3 in Modulating Astrocytic Response and Neuronal Survival Post-Subarachnoid Hemorrhage. [Abstract]2025 Apr 4. PMID: 40183383
Carbenoxolone disodium purchased from MedChemExpress. Usage Cited in: Glia. 2025 Apr 4. [Abstract]
Evaluation of GJIC in different cell groups by assessing thespread of fluorescent dye LY in cultured astrocyte syncytia via scrape-loading. The results showed that LYdiffusion was significantly inhibited in cells treated with Carbenoxolone disodium (CBX; 50 μM), similar to the effects of CXCL12 and CXCL11 .
-
PLoS Pathog
Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]2026 Jan 26;22(1):e1013903. PMID: 41587213 -
Biol Reprod
Suppression of FOXO3 by BMP signaling contribute to the different primordial germ cell proliferation between layers and broilers. [Abstract]2025 May 13;112(5):942-954. PMID: 39987556 -
Food Chem Toxicol
Unveiling the mechanisms of trichloroethylene hypersensitivity syndrome: Exploring the role of connexin 43 gap junctions in severe skin damage. [Abstract]2024 May:187:114594. PMID: 38485042 -
Solvent & Solubility
H2O : 50 mg/mL (81.34 mM; Need ultrasonic)
DMSO : 11.67 mg/mL (18.98 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.03 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.03 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 6.25 mg/mL (10.17 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. W L Duax, et al. Steroid Dehydrogenase Structures, Mechanism of Action, and Disease. Vitam Horm. 2000;58:121-48. [Content Brief]
[2]. Hossein Hosseinzadeh, et al. Anticonvulsant, Sedative and Muscle Relaxant Effects of Carbenoxolone in Mice. BMC Pharmacol. 2003 Apr 29;3:3. [Content Brief]
[3]. Ismar R Haga, et al. Carbenoxolone-mediated Cytotoxicity Inhibits Vaccinia Virus Replication in a Human Keratinocyte Cell Line. Sci Rep. 2018 Nov 16;8(1):16956. [Content Brief]
[4]. Ismar R Haga, et al. Carbenoxolone-mediated cytotoxicity inhibits Vaccinia virus replication in a human keratinocyte cell line. Sci Rep. 2018 Nov 16;8(1):16956. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 1.6268 mL | 8.1338 mL | 16.2676 mL | 40.6689 mL |
| 5 mM | 0.3254 mL | 1.6268 mL | 3.2535 mL | 8.1338 mL | |
| 10 mM | 0.1627 mL | 0.8134 mL | 1.6268 mL | 4.0669 mL | |
| 15 mM | 0.1085 mL | 0.5423 mL | 1.0845 mL | 2.7113 mL | |
| H2O | 20 mM | 0.0813 mL | 0.4067 mL | 0.8134 mL | 2.0334 mL |
| 25 mM | 0.0651 mL | 0.3254 mL | 0.6507 mL | 1.6268 mL | |
| 30 mM | 0.0542 mL | 0.2711 mL | 0.5423 mL | 1.3556 mL | |
| 40 mM | 0.0407 mL | 0.2033 mL | 0.4067 mL | 1.0167 mL | |
| 50 mM | 0.0325 mL | 0.1627 mL | 0.3254 mL | 0.8134 mL | |
| 60 mM | 0.0271 mL | 0.1356 mL | 0.2711 mL | 0.6778 mL | |
| 80 mM | 0.0203 mL | 0.1017 mL | 0.2033 mL | 0.5084 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Carbenoxolone disodium Related Classifications
HY-B1367 Related Classifications
Powered by Bioz